A National Resilience facility in Ontario.Business Wire via AP

By Matthew Herper, Jason Mast, and Allison DeAngelis

June 9, 2025

Matthew Herper

[email protected]

Matthew Herper covers medical innovation — both its promise and its perils.

Jason Mast

[email protected]

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason on Signal at JasonMast.05.

Allison DeAngelis

[email protected]

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud. You can reach Allison on Signal at AllisonDeAngelis.01.

National Resilience, a startup that has raised over $2 billion by promising to transform drug manufacturing, said Monday that it would “wind down” many of its facilities.  

But what remains of the firm has raised an additional $250 million from existing investors to continue to build its business and seek more capital.

Advertisement

Through a bit of financial engineering, an affiliate of the firm that holds leases for six of the company’s manufacturing facilities is filing for bankruptcy. National Resilience itself is not filing for bankruptcy, a spokesperson said, and will continue operating facilities in Toronto and Ohio, where it manufactures GLP-1 drugs for Eli Lilly. 

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe
, ,
Submit a correction requestReprints

  1. Matthew Herper

    Senior Writer, Medicine, Editorial Director of Events

    Matthew Herper covers medical innovation — both its promise and its perils.

  2. Jason Mast

    General Assignment Reporter

    Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason on Signal at JasonMast.05.

  3. Allison DeAngelis

    Biotech Startups and Venture Capital Reporter

    Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud. You can reach Allison on Signal at AllisonDeAngelis.01.